Home / Health / Interpol Flags Fake Weight-Loss Drugs: India's Regulators on High Alert
Interpol Flags Fake Weight-Loss Drugs: India's Regulators on High Alert
28 Jul
Summary
- India's drug regulator alerted states to monitor semaglutide batches.
- An Interpol alert flagged counterfeit semaglutide detected in Austria.
- Demand for weight-loss drugs like semaglutide has significantly increased.
State drug regulators in India have been instructed to intensify their monitoring of distribution networks and crack down on any suspect semaglutide batches. This directive was issued after an Interpol alert, originating from Austria, flagged the detection of a counterfeit version of the widely sought-after weight-loss drug.
The Central Drugs Standard Control Organization (CDSCO) communicated the alert to all states and union territories, emphasizing the need for strengthened surveillance and immediate action against any falsified products found. This move is in response to the growing demand for GLP-1 receptor agonists, such as semaglutide, which are increasingly popular for treating type 2 diabetes and obesity.
Health experts caution against the indiscriminate use of semaglutide, stressing that it should only be administered for specific medical indications under strict medical supervision. Pharmaceutical exporters noted that while the alert concerns a foreign entity, it reinforces the importance of vigilance across the entire supply chain, from legitimate prescriptions to CDSCO-approved distribution networks.
The Indian semaglutide market is experiencing substantial growth, projected to reach $347.5 million by 2035. This expansion follows the patent expiry of semaglutide in India on March 20, 2026, which has enabled domestic manufacturers to launch generic versions, further increasing market accessibility and underscoring the need for robust regulatory oversight.
